Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography

Open access
Therriault, Joseph, Vermeiren, Marie, Servaes, Stijn, Tissot, Cécile, Ashton, Nicholas J., Benedet, Andréa Lessa, Karikari, Thomas K., Lantero-Rodriguez, Juan, Brum, Wagner S., Lussier, Firoza Z., Bezgin, Gleb, Stevenson, Jenna, Rahmouni, Nesrine, Kunach, Peter, Wang, Yi-Ting, Fernandez-Arias, Jaime, Socualaya, Kely Quispialaya, Macedo, Arthur C., Ferrari-Souza, João Pedro, Ferreira, Pâmela C. L., Bellaver, Bruna, Leffa, Douglas T., Zimmer, Eduardo R., Vitali, Paolo, Soucy, Jean-Paul, Triana-Baltzer, Gallen, Kolb, Hartmuth C., Pascoal, Tharick A., Saha-Chaudhuri, Paramita, Gauthier, Serge, Zetterberg, Henrik, Blennow, Kaj, Rosa-Neto, Pedro·2023·JAMA Neurology

Abstract

Importance: The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised questions about their preferential association with the hallmark pathologies of Alzheimer disease (AD): amyloid-β plaques and tau neurofibrillary tangles. Objective: To determine whether cerebrospinal fluid (CSF) and plasma p-tau biomarkers preferentially reflect cerebral β-amyloidosis or neurofibrillary tangle aggregation measured with positron emission tomography (PET). Design, Setting, and Participants: This was a cross-sectional study of 2 observational cohorts: the Translational Biomarkers in Aging and Dementia (TRIAD) study, with data collected between October 2017 and August 2021, and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), with data collected between September 2015 and November 2019. TRIAD was a single-center study, and ADNI was a multicenter study. Two independent subsamples were derived from TRIAD. The first TRIAD subsample comprised individuals assessed with CSF p-tau (p-tau 181, p-tau 217, p-tau 231, p-tau 235), [18 F]AZD4694 amyloid PET, and [18 F]MK6240 tau PET. The second TRIAD subsample included individuals assessed with plasma p-tau (p-tau 181, p-tau 217, p-tau 231), [18 F]AZD4694 amyloid PET, and [18 F]MK6240 tau PET. An independent cohort from ADNI comprised individuals assessed with CSF p-tau 181, [18 F]florbetapir PET, and [18 F]flortaucipir PET. Participants were included based on the availability of p-tau and PET biomarker assessments collected within 9 months of each other. Exclusion criteria were a history of head trauma or magnetic resonance imaging/PET safety contraindications. No participants who met eligibility criteria were excluded. Exposures: Amyloid PET, tau PET, and CSF and plasma assessments of p-tau measured with single molecule array (Simoa) assay or enzyme-linked immunosorbent assay. Main Outcomes and Measures: Associations between p-tau biomarkers with amyloid PET and tau PET. Results: A total of 609 participants (mean [SD] age, 66.9 [13.6] years; 347 female [57%]; 262 male [43%]) were included in the study. For all 4 phosphorylation sites assessed in CSF, p-tau was significantly more closely associated with amyloid-PET values than tau-PET values (p-tau 181 difference, 13%; 95% CI, 3%-22%; P = .006; p-tau 217 difference, 11%; 95% CI, 3%-20%; P = .003; p-tau 231 difference, 15%; 95% CI, 5%-22%; P < .001; p-tau 235 difference, 9%; 95% CI, 1%-19%; P = .02) . These results were replicated with plasma p-tau 181 (difference, 11%; 95% CI, 1%-22%; P = .02), p-tau 217 (difference, 9%; 95% CI, 1%-19%; P = .02), p-tau 231 (difference, 13%; 95% CI, 3%-24%; P = .009), and CSF p-tau 181 (difference, 9%; 95% CI, 1%-21%; P = .02) in independent cohorts. Conclusions and Relevance: Results of this cross-sectional study of 2 observational cohorts suggest that the p-tau abnormality as an early event in AD pathogenesis was associated with amyloid-β accumulation and highlights the need for careful interpretation of p-tau biomarkers in the context of the amyloid/tau/neurodegeneration, or A/T/(N), framework.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2022.4485

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 272

Metadata

Authors
Therriault, J., Vermeiren, M., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Lussier, F. Z., Bezgin, G., Stevenson, J., Rahmouni, N., Kunach, P., Wang, Y.-T., Fernandez-Arias, J., Socualaya, K. Q., Macedo, A. C., Ferrari-Souza, J. P., Ferreira, P. C. L., Bellaver, B., Leffa, D. T., Zimmer, E. R., Vitali, P., Soucy, J.-P., Triana-Baltzer, G., Kolb, H. C., Pascoal, T. A., Saha-Chaudhuri, P., Gauthier, S., Zetterberg, H., Blennow, K., & Rosa-Neto, P.
Venue
JAMA Neurology
Published
2023-02-01
Volume
80
Issue
2
Pages
188
ISSN
2168-6149 (ISSN-L)
OpenAlex
W4311201147
Cited by
272
References
53
FWCI
31.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. https://app.cochat.ai/papers/10.1001/jamaneurol.2022.4485
The paper
Therriault, J., Vermeiren, M., Servaes, S., Tissot, C., Ashton, N. J., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Brum, W. S., Lussier, F. Z., Bezgin, G., Stevenson, J., Rahmouni, N., Kunach, P., Wang, Y.-T., Fernandez-Arias, J., Socualaya, K. Q., Macedo, A. C., Ferrari-Souza, J. P., . . . Rosa-Neto, P. (2023). Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2022.4485

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.